Compare Stocks

Merck (MRK), known as MSD outside of the U.S. and Canada, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA,

Merck (MRK), known as MSD outside of the U.S. and Canada, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA,

Merck (MRK), known as MSD outside of the U.S. and Canada, announced the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted a positive opinion recommending

The company said, “Manufacturing is a core component of Moderna’s (MRNA) integrated mRNA platform, supporting commercial vaccine supply, strategic partnerships and the potential launch of individualized cancer therapies. Manufacturing operations

Guggenheim raised the firm’s price target on Surrozen (SRZN) to $80 from $42 and keeps a Buy rating on the shares. Following Merck’s (MRK) full disclosure of Remigromig in DME

CoreWeave’s stock rose 24%.

Merck (MRK) announced the presentation of “positive” results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide, an investigational

Adagene (ADAG) announced completion of enrollment in its randomized Phase 2 dose-optimization trial of muzastotug, a masked, anti-CTLA-4 SAFEbody, in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda, in patients with

As previously reported, Leerink downgraded Halozyme (HALO) to Market Perform from Outperform with a price target of $117, up from $110, driven by financial model revisions, changing the discount rate

Merck (MRK) announced the initiation of ENHANCE-3, a Phase 3 randomized clinical trial evaluating Ohtuvayre (ensifentrine) for the prevention of chronic obstructive pulmonary disease exacerbations in adult patients receiving standard